Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLIBRI: Nivolumab + Ipilimumab Before Standard Chemoradiotherapy in Cervical Cancer
2019-002271-34Phase 2Completed
- Sponsor
- Arcagy-Gineco
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in cervical squamous cell carcinoma (CSCC), sponsored by Arcagy-Gineco. Primary endpoint: Primary: CD8+/FOXP3+ lymphocyte ratio change. Started Jan 2021; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on 2019-002271-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002271-34.